Literature DB >> 28470714

Fibroblast growth factor-mediated crosstalk in cancer etiology and treatment.

N S Clayton1, A S Wilson1, E P Laurent1, R P Grose1, E P Carter1.   

Abstract

It is becoming increasingly evident that multiple cell types within the tumor work together to drive tumour progression and impact on both the response to therapy and the dissemination of tumour cells throughout the body. Fibroblast growth factor signalling (FGF) is perturbed in a number of tumors, serving to drive tumor cell proliferation and migration, but also has a central role in orchestrating the plethora of cells that comprise the tumor microenvironment. This review focuses on how this family of signalling molecules can influence the interactions between tumor cells and their surrounding environment. Unraveling the complexities of FGF signalling between the distinct cell types of a tumor may identify additional opportunities for FGF-targeted compounds in therapy and could help combat drug resistance. Developmental Dynamics 246:493-501, 2017.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  FGF; cancer; cell signaling

Mesh:

Substances:

Year:  2017        PMID: 28470714     DOI: 10.1002/dvdy.24514

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  8 in total

1.  Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.

Authors:  Helen E Burston; Oliver A Kent; Laudine Communal; Molly L Udaskin; Ren X Sun; Kevin R Brown; Euihye Jung; Kyle E Francis; Jose La Rose; Joshua Lowitz; Ronny Drapkin; Anne-Marie Mes-Masson; Robert Rottapel
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

Review 2.  2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology.

Authors:  Richard J Epstein; Li Jun Tian; Yan Fei Gu
Journal:  J Oncol       Date:  2021-04-30       Impact factor: 4.375

3.  Emerging Roles of Fibroblast Growth Factor 10 in Cancer.

Authors:  Natasha S Clayton; Richard P Grose
Journal:  Front Genet       Date:  2018-10-24       Impact factor: 4.599

4.  Integrated Analysis of Transcriptome and Prognosis Data Identifies FGF22 as a Prognostic Marker of Lung Adenocarcinoma.

Authors:  Hong-Yan Liu; Hui Zhao; Wen-Xing Li
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

5.  LCTL Is a Prognostic Biomarker and Correlates With Stromal and Immune Infiltration in Gliomas.

Authors:  Jun Su; Qianquan Ma; Wenyong Long; Hailin Tang; Changwu Wu; Mei Luo; Xiangyu Wang; Kai Xiao; Yang Li; Qun Xiao; Chi Zhang; Haoyu Li; Qing Liu
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

6.  Differential responses to kinase inhibition in FGFR2-addicted triple negative breast cancer cells: a quantitative phosphoproteomics study.

Authors:  Debbie L Cunningham; Adil R Sarhan; Andrew J Creese; Katherine P B Larkins; Hongyan Zhao; Harriet R Ferguson; Katie Brookes; Anna A Marusiak; Helen J Cooper; John K Heath
Journal:  Sci Rep       Date:  2020-05-14       Impact factor: 4.379

7.  Importance of Translational Research for Targeting Fibroblast Growth Factor Receptor Signaling in Cancer.

Authors:  Klaus Holzmann; Brigitte Marian
Journal:  Cells       Date:  2019-10-02       Impact factor: 6.600

Review 8.  The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives.

Authors:  Maria Francesca Santolla; Marcello Maggiolini
Journal:  Cancers (Basel)       Date:  2020-10-18       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.